

Investor update –15th Oct 12:00pm AEDT | 9:00am AWST

Highlights

- The management team of PYC Therapeutics will host an investor call at 12:00pm AEDT | 11:00am AEST | 9:00am AWST on Thursday the 15th of October and invites shareholders to register for the discussion through the link below

Announcement

PYC Therapeutics Limited, (ASX: PYC) ('The Company' or 'PYC') is a precision medicine company developing new treatments for severe unmet patient needs. The Company advises that it will host an investor call at 12:00pm AEDT | 11:00am AEST | 9:00am AWST on the 15th of October to discuss recent developments in the expansion of the Company's drug development pipeline as well as providing an update on progress in the Company's lead drug development program.

Participants can register here for the dial in details:

<https://zoom.us/meeting/register/tJYrdO-sqz0rEtyIWzTVHHImZ8RQbeaDWmQ0>

This ASX announcement was approved and authorised for release by the Board of PYC Therapeutics Limited

ENDS For further information, please contact:

INVESTORS

Kaggen Ausma
CBO
info@pyctx.com

About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a drug development company solving a major challenge in the development of a revolutionary new class of drugs – delivering large drugs into cells. Cell Penetrating Peptides (CPPs) can overcome ‘the delivery challenge’ and provide access for a wide range of potent and precise drug ‘cargoes’ to the ‘undruggable genome’ – the highest value drug targets that exist inside cells. PYC Therapeutics is using its CPP platform to develop a pipeline of novel therapies with an initial focus on inherited retinal diseases.

Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company’s control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company’s current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

Tel: +61 8 6151 0994

pyctx.com

PYC Therapeutics Limited

ACN 098 391 961